GPCM
ALXN

Granite Point Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Granite Point Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,500
Closed -$551K – 107
2016
Q3 		$551K Sell
4,500
-5,500
-55% -$708K 0.45% 66
2016
Q2 		$1.17M Buy
+10,000
New +$1.42M 1.05% 34
2015
Q3 		– Sell
-1,555
Closed -$281K – 112
2015
Q2 		$281K Sell
1,555
-845
-35% -$146K 0.21% 89
2015
Q1 		$416K Hold
2,400
– – 0.3% 80
2014
Q4 		$444K Sell
2,400
-300
-11% -$55.6K 0.41% 65
2014
Q3 		$448K Hold
2,700
– – 0.46% 70
2014
Q2 		$422K Sell
2,700
-1,000
-27% -$158K 0.31% 67
2014
Q1 		$563K Sell
3,700
-6,300
-63% -$1M 0.5% 78
2013
Q4 		$1.33M Buy
+10,000
New +$1.2M 0.8% 48

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return